BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 26176803)

  • 1. Coexisting Prolactinoma and Primary Aldosteronism: Is There a Pathophysiological Link?
    Williams TA; Dietz AS; Theodoropoulou M; Riester A; Fischer E; Burrello J; Treitl M; Geyer L; Veglio F; Bidlingmaier M; Schopohl J; Beuschlein F; Mulatero P; Reincke M
    J Clin Endocrinol Metab; 2015 Sep; 100(9):E1262-9. PubMed ID: 26176803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Basal, pulsatile, entropic, and 24-hour rhythmic features of secondary hyperprolactinemia due to functional pituitary stalk disconnection mimic tumoral (primary) hyperprolactinemia.
    Veldman RG; Frölich M; Pincus SM; Veldhuis JD; Roelfsema F
    J Clin Endocrinol Metab; 2001 Apr; 86(4):1562-7. PubMed ID: 11297584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Role of hypothalamo-hypophyseal-adrenal axis in the pathogenesis of arterial hypertension in patients with prolactinoma of the anterior lobe of the hypophysis].
    Mychka VB; Chazova IE; Dmitriev VV; Masenko VP
    Ter Arkh; 2000; 72(9):10-3. PubMed ID: 11076407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Long-acting and repeatable dose bromocriptine in the prolonged treatment of prolactinoma].
    Pereira JL; García-Luna PP; Leal-Cerro A; Cortés A; Trujillo F; Villamil F; Vaquero F; Revuelta M; Astorga R
    Med Clin (Barc); 1994 Jun; 103(2):59-64. PubMed ID: 8051973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Some forms of big big prolactin behave as a complex of monomeric prolactin with an immunoglobulin G in patients with macroprolactinemia or prolactinoma.
    Cavaco B; Leite V; Santos MA; Arranhado E; Sobrinho LG
    J Clin Endocrinol Metab; 1995 Aug; 80(8):2342-6. PubMed ID: 7629227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A patient with a prolactinoma associated with an aldosterone producing adrenal adenoma: differences in dopaminergic regulation of PRL and aldosterone secretion.
    Demura R; Naruse M; Isawa M; Onoda N; Naruse K; Yamakado M; Demura H
    Endocrinol Jpn; 1992 Apr; 39(2):169-76. PubMed ID: 1396349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between high prolactin levels and migraine attacks in patients with microprolactinoma.
    Bosco D; Belfiore A; Fava A; De Rose M; Plastino M; Ceccotti C; Mungari P; Iannacchero R; Lavano A
    J Headache Pain; 2008 Apr; 9(2):103-7. PubMed ID: 18256782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Familial Cancer Clustering in Patients with Prolactinoma.
    Pekic S; Soldatovic I; Miljic D; Stojanovic M; Doknic M; Petakov M; Popovic V
    Horm Cancer; 2019 Feb; 10(1):45-50. PubMed ID: 30196424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolactin-lowering effect of luteinizing hormone-releasing hormone agonist administration in prolactinoma patients.
    Rubio MA; Cabranes JA; Schally AV; Charro AL
    J Clin Endocrinol Metab; 1989 Aug; 69(2):444-7. PubMed ID: 2526819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Germline Prolactin Receptor Mutation Is Not a Major Cause of Sporadic Prolactinoma in Humans.
    Bernard V; Bouilly J; Beau I; Broutin I; Chanson P; Young J; Binart N
    Neuroendocrinology; 2016; 103(6):738-45. PubMed ID: 26641246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term treatment of bromocriptine-intolerant prolactinoma patients with CV 205-502.
    Glaser B; Nesher Y; Barziliai S
    J Reprod Med; 1994 Jun; 39(6):449-54. PubMed ID: 7932398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The characteristics of acromegalic patients with hyperprolactinemia and the differences with hyperprolactinemia patients.
    Huan C; Cui G; Ren Z
    Pak J Pharm Sci; 2015 Mar; 28(2 Suppl):713-8. PubMed ID: 25796163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology.
    Fardella CE; Mosso L; Gómez-Sánchez C; Cortés P; Soto J; Gómez L; Pinto M; Huete A; Oestreicher E; Foradori A; Montero J
    J Clin Endocrinol Metab; 2000 May; 85(5):1863-7. PubMed ID: 10843166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Surgery, dopamine agonist therapy of combined treatment--results in prolactinoma patients after a 12 month follow-up.
    Hildebrandt G; Bauer T; Stracke H; Fassbender WJ; Mueller HW; Agnoli AL; Federlin K; Roosen K
    Zentralbl Neurochir; 1992; 53(3):123-34. PubMed ID: 1414079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Do the limits of serum prolactin in disconnection hyperprolactinaemia need re-definition? A study of 226 patients with histologically verified non-functioning pituitary macroadenoma.
    Karavitaki N; Thanabalasingham G; Shore HC; Trifanescu R; Ansorge O; Meston N; Turner HE; Wass JA
    Clin Endocrinol (Oxf); 2006 Oct; 65(4):524-9. PubMed ID: 16984247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A study of pineal-prolactin interaction: prolactin response to an acute melatonin injection in patients with hyperprolactinemia.
    Lissoni P; Mainini E; Mazzi C; Cattaneo G; Barni S
    J Endocrinol Invest; 1990 Feb; 13(2):85-9. PubMed ID: 2329263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathologic study of 123 cases of prolactin-secreting pituitary adenomas with special reference to multihormone production and clonality of the adenomas.
    Ma W; Ikeda H; Yoshimoto T
    Cancer; 2002 Jul; 95(2):258-66. PubMed ID: 12124824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High prolactin levels may be missed by immunoradiometric assay in patients with macroprolactinomas.
    St-Jean E; Blain F; Comtois R
    Clin Endocrinol (Oxf); 1996 Mar; 44(3):305-9. PubMed ID: 8729527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia.
    Colao A; Di Sarno A; Cappabianca P; Di Somma C; Pivonello R; Lombardi G
    N Engl J Med; 2003 Nov; 349(21):2023-33. PubMed ID: 14627787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and laboratory features greatly overlap in patients with macroprolactinemia or monomeric hyperprolactinemia.
    Vilar L; Naves LA; Freitas MC; Lima M; Canadas V; Albuquerque JL; Lyra R; Azevedo MF; Casulari LA
    Minerva Endocrinol; 2007 Jun; 32(2):79-86. PubMed ID: 17557033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.